ALTSTATION.IO

MetLife, Inc. (MET) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$76.09

Change

+1.02%

Market Cap

$50.14B

Avg Volume

3.7M

Company Overview

MetLife, Inc. provides a wide range of financial services, primarily in the insurance sector. Their offerings include life insurance, annuities, employee benefits, and asset management services. Businesses and individuals are their main customers, utilizing products such as life, dental, and disability insurance, along with retirement solutions. With headquarters in New York, MetLife operates globally, targeting various regions including Asia, Latin America, and Europe.

MetLife is a market leader in the life insurance industry, holding a significant share and competing with other giants like Prudential and AIG. Their competitive edge comes from a robust product portfolio and a strong brand established over decades. However, they face challenges from newer insurtech companies that leverage technology to offer streamlined services. Regulatory changes and market dynamics, especially interest rates, also pose potential threats to their profitability.

Currently, MetLife is focused on growth and modernization. The company is investing heavily in technology to enhance customer experience and improve operational efficiency. Recent strategic milestones include a pivot towards digital platforms and an emphasis on expanding their employee benefits segment. This positions them to capitalize on evolving market demands and to counteract competition from agile newcomers in the space.

Key Financials

Market Cap

$50.14B

Revenue

$77.08B

EBITDA

$5.37B

Gross Margin

20.6%

Profit Margin

4.4%

Revenue Growth

27.6%

Total Cash

$29.18B

Total Debt

$47.87B

Free Cash Flow

N/A

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

15.72

Forward P/E

6.90

Beta

0.74

52-Week High

$87.39

52-Week Low

$65.21

EPS

$4.84

50-Day Avg

$78.71

200-Day Avg

$78.67

Price/Book

1.74

Technical Analysis

Over the past 52 weeks, MetLife, Inc. (MET) has exhibited a generally bearish trend, declining approximately 5.3% from its prior levels. The current price of $76.09 is situated near key support levels around $75, which has held firm on multiple occasions, while resistance is clearly defined at $80, a level it has struggled to exceed since June. The stock has formed a series of lower highs and lower lows, indicating a persistent downward pressure, highlighted by the recent patterns of volatility. In the last few weeks, momentum has been weak, with the stock trading sideways around the $76 level, suggesting a lack of strong buying interest. Currently, the price is approximately 3% above its 52-week support at $73.32, implying caution; while it remains significantly below the 52-week high of $88.54, potential weakness may continue unless a significant reversal occurs.

Recent News and Developments

Here’s a summary of the latest news and developments for MetLife, Inc

(MET) stock in the past week:

1. MetLife Exceeds Q4 2025 Earnings Estimates

MetLife announced its fourth-quarter and full-year 2025 earnings on February 4, 2026, reporting an adjusted operating earnings per share (EPS) of $2.58. This figure surpassed analysts’ consensus estimates of $2.34 by $0.24, marking a 24% increase year-over-year. The financial services provider’s revenue for the quarter also increased by 27.6% compared to the same period last year, reaching $18.61 billion, though it fell below analyst estimates of $31.43 billion.

2. Analyst Downgrade from Evercore ISI

On January 6, 2026, Evercore ISI downgraded MetLife (MET) from “Outperform” to “In Line” and reduced its price target from $108.00 to $97.00. The firm cited potential downside to consensus forward earnings and the stock’s valuation as relatively expensive compared to mid-cap peers as reasons for the downgrade. Evercore ISI also lowered its 2026 earnings estimate for MetLife by approximately 3.5%.

Market Sentiment and Analyst Recommendations

Bull Case

MetLife beat Q4 earnings by 10% ($2.58 vs $2.34 consensus) and posted 27.6% revenue growth, demonstrating operational execution when it matters. The P/E of 15.72 is reasonable for an insurer with $77.08B in annual revenue and a 15-17% ROE target that management reaffirmed. The company expects double-digit adjusted EPS growth near term and projects $25B in free cash flow over 2025-2029, which funds dividends and buybacks. With $29.18B in cash against $47.87B in debt, the balance sheet supports capital returns. The analyst consensus price target of $92.60 implies 22% upside from current levels, and 15 analysts rate it a buy. The stock is trading 13% below its 52-week high, offering a margin of safety for contrarian buyers.

Bear Case

Evercore ISI just downgraded the stock and cut 2026 earnings estimates by 3.5%, signaling analyst confidence is cracking. The stock has declined 5.3% over 52 weeks and formed lower highs and lower lows, a technical pattern that suggests institutional money is leaving. Revenue beat Q4 but missed the quarterly estimate by $12.82B ($18.61B vs $31.43B), a massive shortfall that raises questions about guidance credibility. The debt-to-equity situation is stretched at nearly 2x cash, limiting financial flexibility if underwriting conditions deteriorate. Insurance is cyclical and rate-sensitive; if the Fed cuts rates below the 4.40% assumption baked into 2026 guidance, earnings could compress. The stock is stuck below $80 resistance and near $75 support, trapped in a range with weak momentum.

What to Watch

Monitor Q1 2026 earnings in late April for evidence that the Q4 beat was sustainable or an anomaly. Watch the 10-year Treasury yield against the 4.40% assumption in guidance; if rates fall materially, adjust 2026 EPS expectations down. Track MetLife’s free cash flow conversion against the $25B target over 2025-2029; any miss signals capital return cuts ahead. If the stock breaks below $75 support, the next target is $73.32, which would confirm the bearish technical pattern. Conversely, a sustained move above $80 resistance would signal institutional accumulation and could trigger a retest of the $87-88 range. Watch for any additional analyst downgrades or rating changes in the next 30 days; Evercore’s move may inspire others to follow. Finally, monitor competitive pressure from low-cost digital insurers and any shifts in customer acquisition costs that could pressure margins.

Analyst Consensus

BUY

Based on 15 analyst opinions

Low Target

$75.00

Mean Target

$92.60

High Target

$103.00

Earnings and Financial Data

Sector

Financial Services

Industry

Insurance – Life

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 29, 2026

EPS (Trailing)

$4.84

Dividend Yield

301.0%

Payout Ratio

46.4%

Frequently Asked Questions

Is MET a good stock to buy?

Yes, analysts recommend a “BUY” for MetLife, Inc. with a target price of $92.60. This suggests a significant upside from the current price of $76.09.

What is MET’s price target?

The analyst price target for MET is $92.60. This target implies an upside potential of about 22% based on its current trading price.

Does MET pay a dividend?

Yes, MetLife has a substantial dividend yield of 301.0%. This highlights the company’s commitment to returning value to shareholders.

How does MET’s P/E ratio compare to its peers?

MET’s P/E ratio stands at 15.72, which is competitive within the financial services sector. Its forward P/E of 6.90 indicates strong earnings potential relative to its price.

What is MET’s 52-week price range?

MET’s 52-week range is between $65.21 and $87.39. This range reflects its volatility but also indicates potential for growth as it approaches its highs.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.